Waiting for a pandemic
After a quiet period of nearly 30 years, influenza strains with hemagglutinin types that have not been seen in humans previously started to jump from birds to man, suggesting the risk of a new influenza pandemic. However, in contrast to the situation with all the other influenza pandemics occurring in the 20th century and before, in the 21st century we have sophisticated technologies for diagnosis, therapy and prevention. Modeling of the possible spread of a pandemic suggests that vaccination is by far the only way to eliminate the risk of a new pandemic. In this chapter we review the development of new vaccines against H5N1 viruses, showing that effective vaccines adjuvanted with oil-inwater emulsion are about to be licensed and will soon be available. The race against an influenza pandemic has begun; it is a battle against time that mankind cannot afford to lose.
KeywordsInfluenza Vaccine Influenza Pandemic ADJUVANTED Vaccine Split Vaccine UENZA Virus
Unable to display preview. Download preview PDF.
- 5.Novavax Inc (2007) Press release Novavax announces preclinical results for seasonal influenza vaccine program Google Scholar
- 8.Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, Lalor P, Leamy V, Vahle R, Luke CJ et al (2007) Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccines 3: 157–164Google Scholar
- 11.Nicholson KG, Colgate AE, Podda A, Stephenson I, Wood J, Ypma Y, Zambon MC (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937–1943PubMedCrossRefGoogle Scholar
- 13.Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, Katz JM (2005) Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy. J Infect Dis 191: 1210–1215PubMedCrossRefGoogle Scholar
- 15.Zangwill K, Campbell J, Noah D, Treanor J (2007) Evaluation of a third dose of subvirion H5N1 influenza vaccine (rgA/Vietnam/1203/04xPRB) in healthy adults. In: Options for the Control of Influenza VI (Toronto, June 17-23, 2007). Abstract no. P737Google Scholar
- 20.Banzhoff A (2007) Antigen-sparing effect of MF59 in Fluad-H5N1. In: Third WHO meeting on evaluation of pandemic influenza prototype vaccines in clinical trials, 157#x2013;16 February 2007, WHO, GenevaGoogle Scholar